Literature DB >> 12830008

Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis.

Raghavakaimal Sreekumar1, Barbara Rosado, Deborah Rasmussen, Michael Charlton.   

Abstract

Although the molecular basis for the pathophysiology of nonalcoholic steatohepatitis (NASH) is poorly understood, insulin resistance and mitochondrial dysfunction are physiologic hallmarks of this condition. We sought evidence of a transcriptional or pretranscriptional basis for insulin resistance and mitochondrial dysfunction through measurement of hepatic gene expression (messenger RNA [mRNA]) using high-density synthetic oligonucleotide microarray analysis (Hu6800 GeneChip, Affymetrix, CA). Global hepatic gene expression was determined in snap-frozen liver biopsy specimens from 4 groups: (1) patients with cirrhotic-stage NASH (n = 6), (2) patients with cirrhosis caused by hepatitis C virus (HCV) (n = 6), (3) patients with cirrhosis secondary to primary biliary cirrhosis (PBC) (n = 6), and (4) healthy controls (n = 6). Genes were considered to be expressed differentially in NASH only if there was a greater than 2-fold difference in abundance of mRNA when compared with each of the control groups. Sixteen genes were uniquely differentially expressed (4 overexpressed and 12 underexpressed) in patients with cirrhotic-stage NASH. Genes that were significantly underexpressed included genes important for maintaining mitochondrial function (copper/zinc superoxide dismutase, aldehyde oxidase, and catalase). Glucose 6-phospatase, alcohol dehydrogenase, elongation factor-TU, methylglutaryl coenzyme A (CoA), acyl CoA synthetase, oxoacyl CoA thiolase, and ubiquitin also were underexpressed in NASH. Genes that were overexpressed in NASH included complement component C3 and hepatocyte-derived fibrinogen-related protein, potentially contributing to impaired insulin sensitivity. In conclusion, these studies provide evidence for a transcriptional or pretranscriptional basis for impaired mitochondrial function (attenuated capacity for the dismutation of reactive oxygen species) and diminished insulin sensitivity (increased acute phase reactants) in patients with histologically progressive NASH. Further studies are required to determine the mechanism and the physiologic significance of these findings.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12830008     DOI: 10.1053/jhep.2003.50290

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  44 in total

1.  Hepatic gene networks in morbidly obese patients with nonalcoholic fatty liver disease.

Authors:  Samer Gawrieh; Tesfaye M Baye; Melanie Carless; James Wallace; Richard Komorowski; David E Kleiner; Deborah Andris; Bassem Makladi; Regina Cole; Michael Charlton; Joanne Curran; Thomas D Dyer; Jac Charlesworth; Russell Wilke; John Blangero; Ahmed H Kissebah; Michael Olivier
Journal:  Obes Surg       Date:  2010-12       Impact factor: 4.129

2.  Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition.

Authors:  Michael Charlton; Anuradha Krishnan; Kimberly Viker; Schuyler Sanderson; Sophie Cazanave; Andrea McConico; Howard Masuoko; Gregory Gores
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-08-11       Impact factor: 4.052

Review 3.  Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future.

Authors:  Emer Fitzpatrick; Anil Dhawan
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

4.  Nutrigenomics analysis reveals that copper deficiency and dietary sucrose up-regulate inflammation, fibrosis and lipogenic pathways in a mature rat model of nonalcoholic fatty liver disease.

Authors:  Savannah Tallino; Megan Duffy; Martina Ralle; María Paz Cortés; Mauricio Latorre; Jason L Burkhead
Journal:  J Nutr Biochem       Date:  2015-05-15       Impact factor: 6.048

5.  A human-type nonalcoholic steatohepatitis model with advanced fibrosis in rabbits.

Authors:  Tomohiro Ogawa; Hideki Fujii; Katsutoshi Yoshizato; Norifumi Kawada
Journal:  Am J Pathol       Date:  2010-05-20       Impact factor: 4.307

6.  Effects of amlodipine, captopril, and bezafibrate on oxidative milieu in rats with fatty liver.

Authors:  Zvi Ackerman; Mor Oron-Herman; Talma Rosenthal; Orit Pappo; Gabriela Link; Ben-Ami Sela; Maria Grozovski
Journal:  Dig Dis Sci       Date:  2007-08-22       Impact factor: 3.199

Review 7.  Non-alcoholic fatty liver disease: an emerging pathological spectrum.

Authors:  Elie Serge Zafrani
Journal:  Virchows Arch       Date:  2003-12-18       Impact factor: 4.064

8.  The Ups and Downs of Insulin Resistance and Type 2 Diabetes: Lessons from Genomic Analyses in Humans.

Authors:  Vicencia Sales; Mary-Elizabeth Patti
Journal:  Curr Cardiovasc Risk Rep       Date:  2012-12-09

Review 9.  The immunopathogenesis of alcoholic and nonalcoholic steatohepatitis: two triggers for one disease?

Authors:  Luca Valenti; Anna Ludovica Fracanzani; Silvia Fargion
Journal:  Semin Immunopathol       Date:  2009-05-14       Impact factor: 9.623

10.  Gene expression patterns in hepatic tissue and visceral adipose tissue of patients with non-alcoholic fatty liver disease.

Authors:  Ancha Baranova; Karen Schlauch; Hazem Elariny; Mohammed Jarrar; Chase Bennett; Clare Nugent; Shobha J Gowder; Zahra Younoszai; Rochelle Collantes; Vikas Chandhoke; Zobair M Younossi
Journal:  Obes Surg       Date:  2007-08       Impact factor: 4.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.